[
  {
    "ts": "2025-11-10T09:17:25+00:00",
    "headline": "Norway wealth fund abstains from Novo board vote; Stock up on dropped Metsera bid",
    "summary": "Investing.com -- Norway’s sovereign wealth fund said on Monday it will abstain from voting on new board members, including the chair, at Novo Nordisk’s extraordinary shareholders’ meeting on November 14.",
    "url": "https://finance.yahoo.com/news/norway-wealth-fund-abstains-novo-091725443.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "38f4b3ac-86d6-30c7-9b70-1e01d9424752",
      "content": {
        "id": "38f4b3ac-86d6-30c7-9b70-1e01d9424752",
        "contentType": "STORY",
        "title": "Norway wealth fund abstains from Novo board vote; Stock up on dropped Metsera bid",
        "description": "",
        "summary": "Investing.com -- Norway’s sovereign wealth fund said on Monday it will abstain from voting on new board members, including the chair, at Novo Nordisk’s extraordinary shareholders’ meeting on November 14.",
        "pubDate": "2025-11-10T09:17:25Z",
        "displayTime": "2025-11-10T09:17:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/norway-wealth-fund-abstains-novo-091725443.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/norway-wealth-fund-abstains-novo-091725443.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T10:05:43+00:00",
    "headline": "Pfizer to Acquire Metsera Under Amended Deal; Novo Nordisk Says No Plan to Increase Offer for Metsera",
    "summary": "Metsera (MTSR) said late Friday it signed an amended merger agreement with Pfizer (PFE) under which",
    "url": "https://finance.yahoo.com/news/pfizer-acquire-metsera-under-amended-100543786.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "c2d6ce71-d9bd-3bf0-93f0-b2a19433e5e1",
      "content": {
        "id": "c2d6ce71-d9bd-3bf0-93f0-b2a19433e5e1",
        "contentType": "STORY",
        "title": "Pfizer to Acquire Metsera Under Amended Deal; Novo Nordisk Says No Plan to Increase Offer for Metsera",
        "description": "",
        "summary": "Metsera (MTSR) said late Friday it signed an amended merger agreement with Pfizer (PFE) under which",
        "pubDate": "2025-11-10T10:05:43Z",
        "displayTime": "2025-11-10T10:05:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-acquire-metsera-under-amended-100543786.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-acquire-metsera-under-amended-100543786.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T09:38:00+00:00",
    "headline": "Novo Nordisk Shares Rise After Withdrawal from Metsera Takeover Battle",
    "summary": "Shares climbed as much as 3.5% in early European trade after Pfizer agreed to buy Metsera in a deal that could be worth more than $10 billion following a heated takeover battle.",
    "url": "https://www.wsj.com/health/pharma/novo-nordisk-shares-rise-after-withdrawal-from-metsera-takeover-battle-89b46614?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "d5b47e8a-d903-348e-98e6-497e6f129b68",
      "content": {
        "id": "d5b47e8a-d903-348e-98e6-497e6f129b68",
        "contentType": "STORY",
        "title": "Novo Nordisk Shares Rise After Withdrawal from Metsera Takeover Battle",
        "description": "",
        "summary": "Shares climbed as much as 3.5% in early European trade after Pfizer agreed to buy Metsera in a deal that could be worth more than $10 billion following a heated takeover battle.",
        "pubDate": "2025-11-10T09:38:00Z",
        "displayTime": "2025-11-10T09:38:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/d5b47e8a-d903-348e-98e6-497e6f129b68/novo-nordisk-shares-rise.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/2372424f5139c905c960e20b3b91cc99",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3RezSUeM_tSmgS.4CLrL0g--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/2372424f5139c905c960e20b3b91cc99.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dkixDZf9CkcNbqHexcQcRw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/2372424f5139c905c960e20b3b91cc99.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/novo-nordisk-shares-rise-after-withdrawal-from-metsera-takeover-battle-89b46614?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T09:18:45+00:00",
    "headline": "Novo Rises After Bowing Out of Metsera Takeover Battle",
    "summary": "Novo, the maker of Wegovy and Ozempic, decided to drop out of the running for Metsera on Saturday morning after Pfizer matched its latest offer in a bidding war that had pushed the price to levels that caused concern the bidders might be overpaying.  Adding to Novo’s obstacles, Metsera said it got a call from the US Federal Trade Commission flagging potential regulatory risks with the proposed Novo deal structure.  Pfizer agreed to pay $65.60 a share in cash for Metsera, as well as up to $20.65 a share contingent on certain milestones.",
    "url": "https://finance.yahoo.com/news/novo-rises-bowing-metsera-takeover-091845437.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "8ceadc74-594e-32d2-a64a-0aea1a5b22f7",
      "content": {
        "id": "8ceadc74-594e-32d2-a64a-0aea1a5b22f7",
        "contentType": "STORY",
        "title": "Novo Rises After Bowing Out of Metsera Takeover Battle",
        "description": "",
        "summary": "Novo, the maker of Wegovy and Ozempic, decided to drop out of the running for Metsera on Saturday morning after Pfizer matched its latest offer in a bidding war that had pushed the price to levels that caused concern the bidders might be overpaying.  Adding to Novo’s obstacles, Metsera said it got a call from the US Federal Trade Commission flagging potential regulatory risks with the proposed Novo deal structure.  Pfizer agreed to pay $65.60 a share in cash for Metsera, as well as up to $20.65 a share contingent on certain milestones.",
        "pubDate": "2025-11-10T09:18:45Z",
        "displayTime": "2025-11-10T09:18:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/08c13e6140038c2411667c1d223dd9e3",
          "originalWidth": 2000,
          "originalHeight": 1334,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fmXrJtbI3H5zCMXkv.hLZw--~B/aD0xMzM0O3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/08c13e6140038c2411667c1d223dd9e3.cf.webp",
              "width": 2000,
              "height": 1334,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2i3MlmOJYQDWFClE3QXhFg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/08c13e6140038c2411667c1d223dd9e3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-rises-bowing-metsera-takeover-091845437.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-rises-bowing-metsera-takeover-091845437.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T10:45:00+00:00",
    "headline": "These Stocks Are Moving the Most Today: Metsera, Pfizer, Nvidia, Tesla, Rumble, CoreWeave, and More",
    "summary": "Metsera stock plunges after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 billion.",
    "url": "https://www.barrons.com/articles/stock-movers-dc8f3538?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "155d3d60-726a-3ca2-8f7c-3c18fd66640c",
      "content": {
        "id": "155d3d60-726a-3ca2-8f7c-3c18fd66640c",
        "contentType": "STORY",
        "title": "These Stocks Are Moving the Most Today: Metsera, Pfizer, Nvidia, Tesla, Rumble, CoreWeave, and More",
        "description": "",
        "summary": "Metsera stock plunges after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 billion.",
        "pubDate": "2025-11-10T10:45:00Z",
        "displayTime": "2025-11-10T10:45:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/155d3d60-726a-3ca2-8f7c-3c18fd66640c/these-stocks-are-moving-the.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/f6c2e51efdaee0a38422551ff9352718",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ev5Hki_Fwvy8oQ_mdjqQBQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/f6c2e51efdaee0a38422551ff9352718.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CgRBHKcdvBB.Vg_3MymuDA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/f6c2e51efdaee0a38422551ff9352718.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-dc8f3538?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "RUM"
            },
            {
              "symbol": "CRWV"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T13:08:23+00:00",
    "headline": "Pfizer clinches $10bn Metsera deal as Novo Nordisk retreats",
    "summary": "Pfizer’s US antitrust law play appears to have won the day, with Metsera choosing the less risky offer.",
    "url": "https://www.pharmaceutical-technology.com/news/pfizer-clinches-10bn-metsera-deal-as-novo-nordisk-retreats/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "1c498665-8183-3df0-88e1-084129aca738",
      "content": {
        "id": "1c498665-8183-3df0-88e1-084129aca738",
        "contentType": "STORY",
        "title": "Pfizer clinches $10bn Metsera deal as Novo Nordisk retreats",
        "description": "",
        "summary": "Pfizer’s US antitrust law play appears to have won the day, with Metsera choosing the less risky offer.",
        "pubDate": "2025-11-10T13:08:23Z",
        "displayTime": "2025-11-10T13:08:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/8bf5b1150e6db893d8f3635c156e3a76",
          "originalWidth": 1024,
          "originalHeight": 683,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_qGsCoQPq.iwzZ2o7.DW6w--~B/aD02ODM7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/8bf5b1150e6db893d8f3635c156e3a76.cf.webp",
              "width": 1024,
              "height": 683,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y4mwwFd6t8W3xpM7xjCc3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/8bf5b1150e6db893d8f3635c156e3a76.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/pfizer-clinches-10bn-metsera-deal-as-novo-nordisk-retreats/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-clinches-10bn-metsera-deal-130823492.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T12:43:57+00:00",
    "headline": "Stocks to Watch Monday: Barrick Mining, Metsera, Rumble, Tyson Foods",
    "summary": "↘️ Centene (CNC), Molina Healthcare (MOH), Oscar Health (OSCR): President Trump said the \"hundreds of billions of dollars\" paid to health insurers under the Affordable Care Act should go directly to the public.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-10-2025/card/stocks-to-watch-monday-metsera-novo-nordisk-nvidia-tyson-foods-q5Dl4ODGmWfLrrD481Zi?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "613177ca-5916-3e85-bfc2-c2c9b0a58872",
      "content": {
        "id": "613177ca-5916-3e85-bfc2-c2c9b0a58872",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Barrick Mining, Metsera, Rumble, Tyson Foods",
        "description": "",
        "summary": "↘️ Centene (CNC), Molina Healthcare (MOH), Oscar Health (OSCR): President Trump said the \"hundreds of billions of dollars\" paid to health insurers under the Affordable Care Act should go directly to the public.",
        "pubDate": "2025-11-10T12:43:57Z",
        "displayTime": "2025-11-10T12:43:57Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/613177ca-5916-3e85-bfc2-c2c9b0a58872/stocks-to-watch-monday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7272dbf1b75e6a9bb4345c97982cd494",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VKDPvX7s1yi.scNXK0JOYw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7272dbf1b75e6a9bb4345c97982cd494.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7AZPRGpxoSyjz5ZEtw_klQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7272dbf1b75e6a9bb4345c97982cd494.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-10-2025/card/stocks-to-watch-monday-metsera-novo-nordisk-nvidia-tyson-foods-q5Dl4ODGmWfLrrD481Zi?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "DEO"
            },
            {
              "symbol": "DGEAF"
            },
            {
              "symbol": "NDTAF"
            },
            {
              "symbol": "ABX.TO"
            },
            {
              "symbol": "TSN"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "QSR"
            },
            {
              "symbol": "CNC"
            },
            {
              "symbol": "MOH"
            },
            {
              "symbol": "OSCR"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "NB2.F"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T12:33:00+00:00",
    "headline": "These Stocks Are Moving the Most Today: Metsera, Pfizer, Nvidia, Tesla, Rumble, Monday.com, CoreWeave, and More",
    "summary": "Metsera falls sharply after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 billion.",
    "url": "https://www.barrons.com/articles/stock-movers-dc8f3538?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "155d3d60-726a-3ca2-8f7c-3c18fd66640c",
      "content": {
        "id": "155d3d60-726a-3ca2-8f7c-3c18fd66640c",
        "contentType": "STORY",
        "title": "These Stocks Are Moving the Most Today: Metsera, Pfizer, Nvidia, Tesla, Rumble, Monday.com, CoreWeave, and More",
        "description": "",
        "summary": "Metsera falls sharply after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 billion.",
        "pubDate": "2025-11-10T12:33:00Z",
        "displayTime": "2025-11-10T12:33:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/155d3d60-726a-3ca2-8f7c-3c18fd66640c/these-stocks-are-moving-the.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/f6c2e51efdaee0a38422551ff9352718",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ev5Hki_Fwvy8oQ_mdjqQBQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/f6c2e51efdaee0a38422551ff9352718.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CgRBHKcdvBB.Vg_3MymuDA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/f6c2e51efdaee0a38422551ff9352718.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-dc8f3538?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "RUM"
            },
            {
              "symbol": "CRWV"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T12:32:00+00:00",
    "headline": "Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.",
    "summary": "The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.",
    "url": "https://www.barrons.com/articles/pfizer-stock-metsera-novo-nordisk-bid-b464be0a?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "71590089-0478-3897-bdd7-84cbe749cc78",
      "content": {
        "id": "71590089-0478-3897-bdd7-84cbe749cc78",
        "contentType": "STORY",
        "title": "Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.",
        "description": "",
        "summary": "The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.",
        "pubDate": "2025-11-10T12:32:00Z",
        "displayTime": "2025-11-10T12:32:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/71590089-0478-3897-bdd7-84cbe749cc78/pfizer-is-buying-weight-loss.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/37b47ecdd24a29c2bdecc18dc259eae9",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9_9AnN0zFgDTfb3AcpsDDw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/37b47ecdd24a29c2bdecc18dc259eae9.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zQTi3fgERMz4fAjnUUvpAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/37b47ecdd24a29c2bdecc18dc259eae9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/pfizer-stock-metsera-novo-nordisk-bid-b464be0a?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T12:00:00+00:00",
    "headline": "Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors",
    "summary": "Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board’s research, drug development and commercialization expertiseSAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previ",
    "url": "https://finance.yahoo.com/news/nurix-therapeutics-appoints-accomplished-biopharmaceutical-120000279.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "e2c74eca-5b4f-3e46-9400-ff86df8682dd",
      "content": {
        "id": "e2c74eca-5b4f-3e46-9400-ff86df8682dd",
        "contentType": "STORY",
        "title": "Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors",
        "description": "",
        "summary": "Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board’s research, drug development and commercialization expertiseSAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previ",
        "pubDate": "2025-11-10T12:00:00Z",
        "displayTime": "2025-11-10T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/2bac359058f8ba3c51bd304c2eb375c0",
          "originalWidth": 124,
          "originalHeight": 59,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bo1Kaht6Lnbt9HxUs8UQiw--~B/aD01OTt3PTEyNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/2bac359058f8ba3c51bd304c2eb375c0.cf.webp",
              "width": 124,
              "height": 59,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/d4ApEsx4wkV_auIuBRdN4w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2bac359058f8ba3c51bd304c2eb375c0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nurix-therapeutics-appoints-accomplished-biopharmaceutical-120000279.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nurix-therapeutics-appoints-accomplished-biopharmaceutical-120000279.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NRIX"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T12:00:00+00:00",
    "headline": "Olema Oncology Reports Third Quarter 2025 Financial and Operating Results",
    "summary": "Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancerInitiated OPERA-02 Phase 3 trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancerPresented compelling new data from Phase 1b/2 study of palazestrant plus ribociclib at ESMO 2025Ended the quarter with $329.0 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWS",
    "url": "https://finance.yahoo.com/news/olema-oncology-reports-third-quarter-120000922.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "9d495d5c-956b-3676-a7e4-afe9b03e6bdc",
      "content": {
        "id": "9d495d5c-956b-3676-a7e4-afe9b03e6bdc",
        "contentType": "STORY",
        "title": "Olema Oncology Reports Third Quarter 2025 Financial and Operating Results",
        "description": "",
        "summary": "Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancerInitiated OPERA-02 Phase 3 trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancerPresented compelling new data from Phase 1b/2 study of palazestrant plus ribociclib at ESMO 2025Ended the quarter with $329.0 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWS",
        "pubDate": "2025-11-10T12:00:00Z",
        "displayTime": "2025-11-10T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/82f34ea0e328e54b1bb3d463e0ef2d0e",
          "originalWidth": 4168,
          "originalHeight": 1197,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/honwmojVcE9.ol.OqfFu6g--~B/aD0xMTk3O3c9NDE2ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/82f34ea0e328e54b1bb3d463e0ef2d0e.cf.webp",
              "width": 4168,
              "height": 1197,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qLxx0NFUNckBxxLcpnSn3A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/82f34ea0e328e54b1bb3d463e0ef2d0e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/olema-oncology-reports-third-quarter-120000922.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/olema-oncology-reports-third-quarter-120000922.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "OLMA"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T11:55:17+00:00",
    "headline": "Metsera Tumbles After Novo Pulls Out of Bidding War With Pfizer",
    "summary": "The shares slumped as much as 16% to $70.12 in US premarket trading.  The stock more than quadrupled from its January initial public offering through Friday’s close.  Novo, the maker of Wegovy and Ozempic, decided to drop out of the running for Metsera on Saturday after Pfizer matched its latest offer in a takeover battle that had caused concern the bidders might be overpaying for an unproven asset.",
    "url": "https://finance.yahoo.com/news/novo-rises-bowing-metsera-takeover-091845437.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "8ceadc74-594e-32d2-a64a-0aea1a5b22f7",
      "content": {
        "id": "8ceadc74-594e-32d2-a64a-0aea1a5b22f7",
        "contentType": "STORY",
        "title": "Metsera Tumbles After Novo Pulls Out of Bidding War With Pfizer",
        "description": "",
        "summary": "The shares slumped as much as 16% to $70.12 in US premarket trading.  The stock more than quadrupled from its January initial public offering through Friday’s close.  Novo, the maker of Wegovy and Ozempic, decided to drop out of the running for Metsera on Saturday after Pfizer matched its latest offer in a takeover battle that had caused concern the bidders might be overpaying for an unproven asset.",
        "pubDate": "2025-11-10T11:55:17Z",
        "displayTime": "2025-11-10T11:55:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/08c13e6140038c2411667c1d223dd9e3",
          "originalWidth": 2000,
          "originalHeight": 1334,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fmXrJtbI3H5zCMXkv.hLZw--~B/aD0xMzM0O3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/08c13e6140038c2411667c1d223dd9e3.cf.webp",
              "width": 2000,
              "height": 1334,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2i3MlmOJYQDWFClE3QXhFg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/08c13e6140038c2411667c1d223dd9e3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-rises-bowing-metsera-takeover-091845437.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-rises-bowing-metsera-takeover-091845437.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]